TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Phase I Study of TK216 in Patients With Relapsed and Refractory Leukemias

This phase I trial studies the side effects and best dose of TK216 and decitabine when given together in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as TK216 and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Overview

• Status: Withdrawn
• Conditions: Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
• Intervention / Treatment: Drug: Group 1: TK216; Drug: Group 2: TK216; Drug: Part 2: Decitabine 10mg/m2; Drug: Part 2: TK216; Drug: Part 2: Decitabine 20 mg/m2; Drug: Expansion Phase TK216; Drug: Expansion Phase Decitabine

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of Ets-family transcription factor inhibitor TK216 (TK216) in patients with relapsed and refractory (R/R) acute myeloid leukemia (AML). (Phase I Dose Escalation) II. To determine the safety and tolerability of TK216 combined with decitabine in patients with relapsed and refractory AML. (Combination Cohort)

SECONDARY OBJECTIVES:

I. Safety profile of TK216 as characterized by adverse event (AE) type, severity, timing and relationship to study drug, as well as laboratory abnormalities in the first and subsequent treatment cycles. (Phase I Dose Escalation) II. To explore the efficacy (complete remission [CR], complete remission without platelet recovery [CRp], complete remission without blood count recovery [CRi], or partial remission [PR]), of TK216 as a single-agent in patients with R/R AML. (Phase I Dose Escalation) III. To assess overall survival (OS), and disease free survival (DFS) in patients with R/R AML treated with TK216. (Phase I Dose Escalation) IV. Duration of disease control defined as first date of disease control identified (either CR/CRp/CRi, PR or SD) until the date of progression. (Phase I Dose Escalation) V. To explore biomarkers of response and resistance in patients with R/R AML treated with TK216. (Phase I Dose Escalation) VI. Safety profile of TK216 in combination with decitabine as characterized by adverse event (AE) type, severity, timing and relationship to study drug, as well as laboratory abnormalities in the first and subsequent treatment cycles. (Combination Cohort) VII. To explore the efficacy (complete remission [CR], complete remission without platelet recovery [CRp], complete remission without blood count recovery [CRi], or partial remission [PR], of TK216 in combination with decitabine in patients with R/R AML. (Combination Cohort) VIII. To assess overall survival (OS), and progression free survival (PFS) in patients with R/R AML treated with TK216 + decitabine. (Combination Cohort) IX. Duration of disease control defined as first date of disease control identified (either CR/CRp/CRi, PR or SD) until the date of progression. (Combination Cohort) X. To explore biomarkers of response and resistance in patients with R/R AML treated with TK216 + decitabine. (Combination Cohort)

OUTLINE: This is a dose-escalation study.

Patients receive TK216 intravenously (IV) continuously on days 1-7 every 21 days, or continuously on days 1-7 and 15-21 every 28 days. Patients also receive decitabine IV over 60 minutes on days 1-10 every 28 days. Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.

• Study Type: Interventional
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with a diagnosis of histologically confirmed relapsed or refractory (R/R) acute myeloid leukemia for which no available standard therapies are indicated or anticipated to result in a durable response
• Patients must not have had leukemia therapy for 14 days prior to starting TK216. However, patients with rapidly proliferative disease may receive hydroxyurea as needed until 24 hours prior to starting therapy on this protocol and during the first cycle of study
• Bilirubin =< 2 mg/dL
• Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) -- or =< 5 x ULN if related to leukemic involvement
• Creatinine =< 1.5 x ULN
• Known cardiac ejection fraction of > or = 45% within the past 3 months
• Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
• A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
• Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol

Exclusion Criteria:

• Pregnant women are excluded from this study because the agent used in this study has the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided
• Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Patient with documented hypersensitivity to any of the components of the therapy program
• Patients with active, uncontrolled central nervous system (CNS) leukemia will not be eligible
• Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use at least 1 form of barrier birth control (such as condom) prior to study entry and for the duration of study participation
• Patients with known history of serous retinopathy will not be eligible
• Prior treatment with TK216

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1 Part 1 TK216: Days 1-7; Patients receive TK216 IV continuously on days 1-7 every 21 days.	Drug: Group 1: TK216; Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
Experimental: Group 2 Part 1 TK216: Days 1-7 and 15-28; Patients receive TK216 IV on days 1-7 and 15-21 every 28 days.	Drug: Group 2: TK216; Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.; Other Names: TK-216; TK216
Experimental: Part 2 TK216 + Decitabine 10mg/m2; Patients receive recommended dose of TK216 from Part 1 plus Decitabine.	Drug: Part 2: Decitabine 10mg/m2; 10mg/m2 by vein on Days 1-10 of a 28 day cycle.; Other Names: Dacogen; Drug: Part 2: TK216; Recommended dose from Part 1.
Experimental: Part 2 TK216 + Decitabine 20 mg/m2; Patients receive recommended dose of TK216 from Part 1 plus Decitabine.	Drug: Part 2: TK216; Recommended dose from Part 1.; Drug: Part 2: Decitabine 20 mg/m2; 20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.; Other Names: Dacogen
Experimental: Expansion Phase: TK216 + Decitabine; All patients in the expansion cohort will receive the RP2D of TK216 and Decitabine.	Drug: Expansion Phase TK216; Expansion cohort will receive the RP2D of TK216; Drug: Expansion Phase Decitabine; Expansion cohort will receive the RP2D of Decitabine; Other Names: Dacogen

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events	Will be tabulated with frequency and percentage by grade, attribution to treatment, and by dose level/schedule.	Up to 30 days
Response rate	Will be estimated alone with 95% confidence interval.	Up to 30 days
Overall survival	Will be estimated using the Kaplan-Meier method.	Up to 1 year
Disease free survival	Will be estimated using the Kaplan-Meier method.	Up to 1 year
Duration of disease control	Will be estimated using the Kaplan-Meier method.	Up to 1 year

Collaborators and Investigators

• Sponsor: M.D. Anderson Cancer Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Tapan Kadia, M.D. Anderson Cancer Center

Publications and helpful links

Helpful Links

• MD Anderson Cancer Center Website

Study record dates

Study Major Dates

• Study Start (Anticipated): March 31, 2019
• Primary Completion (Anticipated): December 31, 2020
• Study Completion (Anticipated): December 31, 2020

Study Registration Dates

• First Submitted: November 20, 2018
• First Submitted That Met QC Criteria: November 21, 2018
• First Posted (Actual): November 23, 2018

Study Record Updates

• Last Update Posted (Actual): May 6, 2019
• Last Update Submitted That Met QC Criteria: May 2, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Decitabine
• Other Study ID Numbers: 2018-0495 (Other Identifier: M D Anderson Cancer Center); P30CA016672 (U.S. NIH Grant/Contract); NCI-2018-02667 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No